Newsquawk Daily European Equity Opening News - 10th November 2026

APAC stocks traded higher as markets continued to claw back the losses from the recent tech slump, while lower oil prices and US-Iran optimism also provided some encouragement. ASX 200 was led higher by outperformance in real estate, industrials and the mining sector amid tailwinds from a lower yield environment in Australia. Nikkei 225 rallied back above the 60,000 level with SoftBank spearheading the advances amid the tech rebound and with stocks unfazed by the weaker-than-expected Household Spending data from Japan. KOSPI benefitted from the tech rally with a sidecar triggered in early trade but is off today's best levels. Hang Seng and Shanghai Comp were positive but lagged behind regional peers as participants digested the somewhat mixed trade data in which dollar-denominated Exports and Imports topped forecasts, although Trade Balance was at a narrower-than-forecast surplus and yuan-denominated Exports slowed.

Chinese Data - Chinese Trade Balance (Oct) 105.28B vs. Exp. 125.8B (Prev. 133.53B); Chinese Imports (Oct YY) 41.6% vs. Exp. 32% (Prev. 31%); Chinese Exports (Oct YY) 35.2% vs. Exp. 33.5% (Prev. 36.3%). (Newswires)

Honda (7267 JT) - H1 2026 (JPY): Net 516bln (prev. 311bln), Revenue 12tln (prev. 10.6tln). (Honda)

SoftBank (9984 JT) - H1 2026 (JPY): Net -768bln (prev. 2.9tln), Revenue 4.24tln (prev. 3.7tln). (Softbank

TSMC (2330 TT) - October revenue rose 31% Y/Y to TWD 32.0bln. (TSMC)

CLOSES: DAX +1.72% at 26,266, FTSE 100 +1.02% at 10,783, CAC 40 +1.16% at 8,233, Euro Stoxx 50 +2.06% at 6,298, AEX +0.84% at 1,130, IBEX 35 +1.93% at 19,743, FTSE MIB +2.69% at 51,400, SMI +1.01% at 14,946, PSI +0.82% at 9,555.

BT (BT/A LN) - BT reportedly will not launch its partnership with SpaceX's (SPCX) Starlink, following on from the controversy surrounding signal failures in Ukraine. CEO Kirby mentioned that they are cautious about how investors and the public would view a BT-Starlink tie-up. Nonetheless, the CEO indicated their eagerness to move forward with Starlink once the "noise has died down". (FT)

UK Defence - UK Defence Secretary Streeting says UK and Russia need a new back channel of communication to avoid the risk of a miscalculation, according to the FT. (FT)

UK Spending - UK Barclays Consumer Spending in October rose 2.3% Y/Y (prev. 2.0% increase in September), which is the largest increase since July 2025. (Barclays)

UK BRC - UK BRC Retail Sales Monitor (Oct YY) 1.1% vs. Exp. 1.2% (Prev. 1.0%). (BRC)

OTHER UK COMPANIES

BROKER MOVES

Bayer (BAYN GY) - Bayer announced today that the US Food and Drug Administration (FDA) has approved SUNHARBO (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). Reducing the risk of a stroke after an initial event is often referred to as secondary stroke prevention. The recommended dosage of SUNHARBO is 50 mg once daily. SUNHARBO is the first approved medicine in the US to target Factor XIa, representing a new approach to reducing the risk of ischemic stroke. (Bayer)

BMW (BMW GY) - Co. secures battery supply deals with LG Energy Solution (373220 KS) and Samsung SDI (006400 KS). (BMW)

Henkel (HEN3 GY) - Final Q3 2026 (EUR): Revenue 5.71bln (prelim. 5.7bln). FY26 Outlook: Organic sales growth: 3-4% (prev. guided 1.5-3.5%). CEO: "Our organic sales growth significantly accelerated in the third quarter, driven by very strong performance in both business units. It is particularly encouraging that we continue to see positive price and volume developments, with volumes increasing for the fifth consecutive quarter." (Henkel)

Infineon (IFX GY) - Q4 2026 (EUR): Revenue 4.71bln (exp. 4.71bln), Adj. EPS 0.60 (prev. 0.34 Y/Y) Gross Margin 41.8% (prev. 40.8% Y/Y). Q1'27 Outlook: Sees Revenue 4.60bln (exp. 4.65bln). FY27 Outlook: Sees initial FY27 Revenue 20bln (exp. 19.8bln). Dividend: The Management Board intends to propose an increase in the dividend of EUR 0.03 to EUR 0.38/shr at the Annual General Meeting in February 2027. CEO: “Infineon closed the fiscal year 2026 with another record quarter and enters the new fiscal year with continued strong momentum". “Supported by an ongoing cyclical recovery and strong demand in our structural growth areas, we expect a significant increase in revenue and profitability in fiscal year 2027. Our semiconductor solutions for data centre power supplies, the expansion and modernization of energy infrastructure, electromobility, and software-defined vehicles will be key contributors. With our product portfolio, innovative strength, and manufacturing capacity, we are well positioned to capitalize on profitable growth opportunities over the long term in these areas and in emerging applications such as robotics and edge AI". (Infineon)

OTHER GERMAN COMPANIES

K+S (SDF GY) - Q3 2026 (EUR): Adj. EBITDA 108mln (exp. 102mln), Revenue 934mln (exp. 900mln). Narrows FY26 EBITDA 700-750mln (prev. guided 680-760mln), citing supply-side constraints. (K+S)

TAG Immobilien (TEG GY) - 9M 2026 (EUR): FFO I 152.7mln, +12% Y/Y. Lifts FFO I outlook for 2026 to 195-200mln (prev. guided 187-197mln). (TAG Immobilien)

BROKER MOVES

GEA (G1A GY) downgraded to Hold from Buy at Berenberg

Airbus (AIR FP) - Co. and TAS awarded IRIS satellite agreement by the French government. Elsewhere, AAR Corp (AIR) signed a multi-year agreement with Airbus Avionics covering its complete portfolio of Airbus radome repairs. The agreement designates AAR as an Airbus-approved repair station in Asia-Pacific, excluding China, for radomes installed on Airbus commercial aircraft. It expands AAR’s existing Airbus repair capabilities for sharklets, elevators, rudders and slats. (Airbus)

OTHER FRENCH COMPANIES

BioMerieux (BIM FP) - Co. receives US FDA 510 (K) clearance. (BioMerieux)

BROKER MOVES

Renault (RNO FP) upgraded to Buy from Hold at Jefferies

BROKER MOVES

Roche (ROP SW) - Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026. Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers. Phase III PrevenTRON study design specifics for trontinemab in preclinical Alzheimer’s disease, which has commenced enrolment. (Roche)

SGS (SGSN SW) - Co. to acquire Deibel Labs, which is expected to close in early 2027. (SGS)

OTHER SWISS COMPANIES

PSP Swiss Property (PSPN SW) - Q3 2026 (CHF): Adj. Net Income 294.6mln (prev. 259.5mln Y/Y), Rental Income 259.3mln (prev. 261.4mln Y/Y). Lifts FY26 Adj. EBITDA to 335mln. (PSP Swiss Property)

BROKER MOVES

Sonova (SOON SW) upgraded to Hold from Underperform at Jefferies

BROKER MOVES

CLOSES: SPX +2.35% at 7,550, NDX +3.40% at 27,908, DJI +2.15% at 52,390, RUT +3.16% at 2,841.

SECTORS: Industrials +3.78%, Consumer Discretionary +3.05%, Technology +2.87%, Materials +2.15%, Communication Services +2.12%, Health +1.94%, Real Estate +1.59%, Utilities +1.54%, Financials +1.42%, Consumer Staples +0.64%, Energy +0.41%.

Anthropic (ANT) - Anthropic plans to proceed with its IPO next week despite AI market volatility, WSJ reports. Investor meetings are scheduled this week, with Nasdaq trading targeted for 19-20th November. Recent reports suggest that some major investors are pushing for a valuation below USD 1.5tln, vs earlier expectations of approximately USD 2tln. The Journal said that Anthropic could still decide to delay the IPO and wait for more favorable market conditions, though doing so would risk sparking panic in the market.

Hims & Hers Health (HIMS) - Shares fell 3.5% in extended trading after a surprise quarterly loss, weaker-than-expected revenue and downgraded FY guidance reflected margin pressure from higher costs associated with branded weight-loss drugs and international expansion, alongside slowing US revenue growth. Q3 EPS -0.14 (exp. 0.06), Q3 revenue USD 890.4mln (exp. 892.8mln). Subscribers +13% Y/Y to nearly 2.8mln, monthly revenue per average subscriber +30% Y/Y to USD 105. Gross margin declined to 57% (vs 74% Y/Y), reflecting a shift towards higher-cost branded weight-loss drugs and international expansion. US revenue +21% Y/Y to USD 657.1mln, while international revenue more than quadrupled to USD 233.3mln. Announced plans to launch unapproved peptide treatments, including NAD+, sermorelin and glutathione, in November, with compounded BPC-157 and TB-500 to follow, after US regulators eased restrictions. CFO expects an immaterial revenue contribution from these treatments through FY26 and highlighted menopause therapies and testosterone testing as drivers of higher revenue per subscriber. Partnerships with Eli Lilly (LLY) and Novo Nordisk (NVO) are expected to support customer retention, although branded weight-loss drugs continue to pressure margins. Sees Q4 revenue between USD 875-895mln (exp. 953.8mln), and adj. EBITDA between USD 70-90mln (exp. 84.7mln), implying an adj. EBITDA margin of 8-10%. Lowers FY26 revenue guidance to between USD 3.13-3.15bln (exp. 3.21bln; prev. saw 3.1-3.3bln) and FY26 adj. EBITDA to between USD 257-277mln (exp. 294.6mln; prev. saw 275-325mln).

Take-Two Interactive (TTWO) - Shares rose 4.6% in extended trading after a narrower than expected quarterly loss and unprecedented pre-orders for Grand Theft Auto VI boosted confidence in its upcoming launch, overshadowing weaker than expected revenue and FY guidance. Q2 adj. EPS 0.99 (exp. 0.97), Q2 revenue USD 1.50bln (exp. 1.61bln), Q2 net loss USD 54mln (vs loss of 133.9mln Y/Y). Net bookings -18% Y/Y to USD 1.60bln (exp. 1.66bln), while recurrent consumer spending -5% Y/Y, accounting for 81% of revenue. CEO said Grand Theft Auto VI pre-orders have reached unprecedented levels ahead of its 19th November launch, with the company expecting a historic year. Sees Q3 EPS between 1.30-1.44 (exp. 1.50), revenue between USD 3.27-3.42bln (exp. 3.42bln), and net bookings between USD 3.35-3.50bln (exp. 3.40bln). Raises FY27 revenue guidance to between USD 7.98-8.18bln (exp. 8.62bln), while seeing FY27 EPS between 0.57-0.75 (exp. 1.66). Reiterates FY27 net bookings guidance between USD 8.0-8.2bln (exp. 8.56bln), supported by the anticipated GTA VI launch and continued expansion opportunities.